Glucomannano (Knojac) proprietà e dosaggio

ConsumerLab fonte

Glucomannano (Knojac) proprietà e dosaggio

Messaggioda Royalsapphire » 07/12/2018, 17:17



E' una fibra.

Proprietà terapeutiche principali: Abbassamento delle LDL ematiche (colesterolo "cattivo").
Proprietà terapeutiche secondarie: Costipazione; diabete (regola i livelli di zuccheri nel sangue); pressione alta; ipertiroidismo; perdita di peso (come spezza-fame).

Meccanismo d'azione: si gonfia nello stomaco a contatto con l'acqua, aumentando 17 volte il proprio volume.

Posologia:
Da 3 a 5 g al giorno in dosi divise, mezzora prima dei pasti.
Per dimagrire occorre una formulazione di almeno 1g di glucomannano 3 volte al giorno.
Tuttavia, ci sono alcuni effetti collaterali per quanto riguarda la forma di glucomannano utilizzata per cui le capsule, a differenza delle compresse, sono ritenute sicure.

SIDE EFFECTS - POSSIBILI EFFETTI COLLATERALI
Alcune persone che hanno assunto glucomannano, lamentavano eccesso di gas, distensione dello stomaco o lieve diarrea. Questi sintomi di solito diminuiscono entro un paio di giorni di trattamento, o con una riduzione del dosaggio.




References

1. Venter CS, Kruger HS, Vorster HH, et al. The effects of dietary fiber component konjac-glucomannan on serum cholesterol levels of hypercholesterolemic subjects. Hum Nutr Food Sci Nutr. 1987;41F:55-61.

2. Reffo GC. Glucomannan in hypertensive outpatients: pilot clinical trial. Curr Ther Res. 1988;44:22-27.

3. Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Ther Res. 1990;47:753-758.

4. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr. 1995;61:585-589.

5. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

6. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;(suppl 3):190-197.

7. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.

8. Reffo GC. Glucomannan in hypertensive outpatients: pilot clinical trial. Curr Ther Res. 1988;44:22-27.

9. Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Res Ther. 1990;47:753-758.

10. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;(suppl 3):190-197.

11. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.

12. Signorelli P, Croce P, Dede A. Clinical study on the use of a glucomannan and lactulose association in pregnancy constipation [in Italian; English abstract]. Minerva Ginecol. 1996;48:577-582.

13. Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol. 1993;28:133-136.

14. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

15. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;(suppl 3):190-197.

16. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

17. Hopman WP, Houben PG, Speth PA, et al. Glucomannan prevents postprandial hypoglycaemia in patients with previous gastric surgery. Gut. 1988;29:930-934.

18. Signorelli P, Croce P, Dede A. Clinical study on the use of a glucomannan and lactulose association in pregnancy constipation [in Italian; English abstract]. Minerva Ginecol. 1996;48:577-582.

19. Staiano A, Simeone D, Del Giudice E, et al. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. J Pediatr. 2000;136:41-45.

20. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr. 1995;61:585-589.

21. Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Res Ther. 1990;47:753-758.

22. Venter CS, Kruger HS, Vorster HH, et al. The effects of dietary fiber component konjac-glucomannan on serum cholesterol levels of hypercholesterolemic subjects. Hum Nutr Food Sci Nutr. 1987;41F:55-61.

23. Reffo GC. Glucomannan in hypertensive outpatients: pilot clinical trial. Curr Ther Res. 1988;44:22-27.

24. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

25. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.

26. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.

27. Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Ther Res. 1990;47:753-758.

28. Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol. 1993;28:133-136.

29. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

30. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.

31. Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Curr Ther Res. 1990;47:753-758.

32. Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol. 1993;28:133-136.

33. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.

34. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;(suppl 3):190-197.

35. Gaudry P. Glucomanna diet tablets [letter]. Med J Aust. 1985;142:204.

36. Henry DA, Mitchell AS, Aylard J, et al. Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed). 1986;292:591-592.

37. Chen HL, Sheu WH, Tai TS, et al. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects-a randomized double-blind trial. J Am Coll Nutr. 2003;22:36-42.

38. Chen HL, Cheng HC, Liu YJ et al. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. Nutrition. 2006 Oct 3 [Epub ahead of print]

39. Azezli AD, Bayraktaroglu T, Orhan Y. The use of konjac glucomannan to lower serum thyroid hormones in hyperthyroidism. J Am Coll Nutr. 2007;26:663-668.

40. Chen HL, Cheng HC, Wu WT, et al. Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults: a placebo-controlled, diet-controlled trial. J Am Coll Nutr. 2008;27:102-108.

41. Vasques CA, Rossetto S, Halmenschlager G, et al. Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity. Phytother Res. 2008;22:1135-1140.

42. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167-1175.
  • 0

:tao: :rose: :mask: :luce: :home1:
Avatar utente
Royalsapphire
Admin
 
Stato:
Messaggi: 13231
Iscritto il: 12/11/2012, 18:07
Località: Svizzera
Occupazione: Farmacista e Counselor
Citazione: "Sii il cambiamento che vuoi vedere nel mondo" (Gandhi)
Genere: Femminile

Glucomannano (Knojac) proprietà e dosaggio

Messaggioda penombra » 07/12/2018, 20:58



costo? Si può' usare la nota 13?
Se è a pagamento quante compresse ci sono?
  • 0

penombra
Amico level six
 
Stato:
Messaggi: 269
Iscritto il: 19/10/2015, 22:34
Località: italia
Genere: Maschile


Torna a MyHelp Integratori

Chi c’è in linea in questo momento?

Visitano il forum: Nessuno e 2 ospiti

Reputation System ©'